Moderna Stock Jumps 7% Near 52-Week High Ahead of Nasdaq-100 Entry

Moderna Inc. (NASDAQ: MRNA) shares closed 6.95% higher at $203.21 on Monday as the vaccine maker approaches its scheduled addition to the Nasdaq-100 before Friday’s market open.

The stock traded as high as $205.77 during the session and finished 2.72% below its $208.90 52-week high. Moderna’s gain also far outpaced the S&P 500’s 0.66% advance Monday.

The Nasdaq-100 tracks 100 of the largest non-financial companies listed on Nasdaq and is tracked by more than 200 investment products representing over $800 billion in assets under management, according to the exchange.

Nasdaq-100 Switch Follows Warner Bros. Deal

Warner Bros. Discovery is leaving the benchmark as its acquisition by Paramount Skydance moves toward completion. The companies said the transaction was expected to close Oct. 6, subject to customary closing conditions.

Moderna was already one of the market’s biggest gainers before the Nasdaq-100 announcement. Its shares had increased more than sixfold during 2026, lifting its market value to roughly $75 billion when the index change was announced, Reuters reported.

The related tokenized instrument also traded higher. Moderna Tokenized bStocks (MRNAB) was trading at $203.54, up 7.74% over the previous 24 hours, according to CoinMarketCap. MRNAB is a separate tokenized instrument that trades over a 24-hour window, making its performance not directly comparable to Moderna’s regular Nasdaq session.

COO Change Takes Effect Monday

Monday also marked the effective date of Juan Andres’ return to Moderna as chief operating officer, a newly created position. Moderna said Andres will report to Chief Executive Stéphane Bancel and serve on the executive committee as the company expands its operations and prepares for the potential launch and scale-up of oncology treatment intismeran autogene.

The company also announced that Jerh Collins, its chief technical operations and quality officer, had decided to retire.

Citi Flags Valuation Risk

Separately, Citi recently took a sharply more cautious view of the stock. The bank downgraded Moderna to Sell from Neutral on Sept. 30 while raising its price target to $80 from $60, arguing that the stock’s rally had pushed expectations for the oncology pipeline too far.

According to CNBC, Citi analyst Geoff Meacham said Moderna had risen 222% since interim results from its INTerpath-001 cancer trial and argued that a share price around $200 would require roughly $26 billion in annual cancer sales under the firm’s assumptions. The new $80 target sits about 60.6% below Monday’s $203.21 closing price, underscoring the valuation gap between Citi’s assessment and the market price after Moderna’s latest advance.